Trial Profile
The Safety , Tolerability and Efficacy of Dronabinol, a Synthetic Endocannabinoid Receptor Agonist, for the Treatment of Nausea and Vomiting in Patients With Familial Dysautonomia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2019
Price :
$35
*
At a glance
- Drugs Dronabinol (Primary)
- Indications Nausea and vomiting
- Focus Adverse reactions; Therapeutic Use
- 11 Jun 2019 Planned End Date changed from 1 Mar 2020 to 22 Mar 2019.
- 11 Jun 2019 Planned primary completion date changed from 1 Mar 2020 to 22 Mar 2019.
- 11 Jun 2019 Status changed from recruiting to withdrawn prior to enrolment.